TY - JOUR
T1 - Genetic variations and clinical features associated with burning sensation due to topical tacrolimus in patients with atopic dermatitis
AU - Lee, Ju Yeong
AU - Kang, Hyun
AU - Kim, Eunjung
AU - Noh, Shinae
AU - Lee, Hyeyoung
AU - Choi, Eung Ho
N1 - Publisher Copyright:
© 2024 The Author(s). JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2024/12
Y1 - 2024/12
N2 - Background: Topical tacrolimus has been used as one of the treatment options for atopic dermatitis (AD). A burning sensation is the most common side effect of topical tacrolimus. Objectives: This study was designed to identify genetic variations and clinical features to predict burning sensation by topical tacrolimus in patients with AD. Methods: Patients with AD who had applied topical tacrolimus were classified according to the presence of a burning sensation. We compared the patients' demographics and blood test results, including serum eosinophil, serum immunoglobulin E and multiple allergen simultaneous test. Furthermore, the frequency of variations in barrier- (KLK7, FLG 3321delA, FLG K4022X, SPINK5 1156, SPINK5 1188, SPINK5 2475) and immune response- (DEFB1, KDR, CDKAL1, IL-5RA, IL-9, IL-12RB1, IL-12RB2, IL-17RA) related genes was compared between two groups by reverse blot hybridization assay of the buccal mucosa. Results: Among 206 patients with AD using topical tacrolimus, 34 (16.5%) complained of a burning sensation. The burning sensation was associated with severe AD and a family history of atopic disease. Furthermore, with statistical significance, a heterozygous mutation in the filaggrin gene (FLG K4022X) was more frequent in AD patients with a burning sensation due to topical tacrolimus. However, no other significant genetic differences were observed between them. Conclusions: A burning sensation caused by topical tacrolimus can be expected in AD patients with severe symptoms, a family history of atopy and a genetic variation such as FLG K4022X.
AB - Background: Topical tacrolimus has been used as one of the treatment options for atopic dermatitis (AD). A burning sensation is the most common side effect of topical tacrolimus. Objectives: This study was designed to identify genetic variations and clinical features to predict burning sensation by topical tacrolimus in patients with AD. Methods: Patients with AD who had applied topical tacrolimus were classified according to the presence of a burning sensation. We compared the patients' demographics and blood test results, including serum eosinophil, serum immunoglobulin E and multiple allergen simultaneous test. Furthermore, the frequency of variations in barrier- (KLK7, FLG 3321delA, FLG K4022X, SPINK5 1156, SPINK5 1188, SPINK5 2475) and immune response- (DEFB1, KDR, CDKAL1, IL-5RA, IL-9, IL-12RB1, IL-12RB2, IL-17RA) related genes was compared between two groups by reverse blot hybridization assay of the buccal mucosa. Results: Among 206 patients with AD using topical tacrolimus, 34 (16.5%) complained of a burning sensation. The burning sensation was associated with severe AD and a family history of atopic disease. Furthermore, with statistical significance, a heterozygous mutation in the filaggrin gene (FLG K4022X) was more frequent in AD patients with a burning sensation due to topical tacrolimus. However, no other significant genetic differences were observed between them. Conclusions: A burning sensation caused by topical tacrolimus can be expected in AD patients with severe symptoms, a family history of atopy and a genetic variation such as FLG K4022X.
KW - atopic dermatitis
KW - burning sensation
KW - genetic variation
KW - topical tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=85197390784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85197390784&partnerID=8YFLogxK
U2 - 10.1002/jvc2.497
DO - 10.1002/jvc2.497
M3 - Article
AN - SCOPUS:85197390784
SN - 2768-6566
VL - 3
SP - 1580
EP - 1586
JO - JEADV Clinical Practice
JF - JEADV Clinical Practice
IS - 5
ER -